Wen Jiang MD, PhD

Associate or Senior Editor, Nature Biomedical Engineering Job Title: Associate or Senior Editor, Nature Biomedical Engineering Organization: Nature Portfolio Location: New York, Jersey City, Shanghai or Beijing – Hybrid Working Closing date: August 20, 2025 ...

My colleagues at Nature Biomedical Engineering @natbiomedeng.nature.com are hiring an associate or senior editor. Ideal applicant will have expertise in immunology, immunotherapy, or immuno-oncology.

Please feel to ask me questions!

springernature.wd3.myworkdayjobs.com/SpringerNatu...

It also didn’t say if it’s r01, r21, r03, or project lead on spore/p01 etc…just active nih grants. So presumably if you had 2 active r21s, you are pretty much done for?

I don’t think any NOA has been released from June council. Can your application remain being considered if nci budget later is adjusted as long as it remains pending in era commons?

it will apply to application reviewed in June nci council too. I don’t think any NOA has been released from that council meeting.

Does mPI count?

Congrats to Adam Grippin, a resident in the radiation oncology program @mdanderson.bsky.social , and soon to be physician scientist, on his latest commentary in @natrevimmunol.nature.com, highlighting a new cell surface mapping technique with implication in understanding immune cell functions.

Congrats John!

Congrats on a new commentary from Ben & @bettykimmdphd.bsky.social @natrevimmunol.nature.com on a preprint detailing a pan-cancer antigen atlas for human cancers. @mdanderson.bsky.social

A Generative Artificial Intelligence Copilot for Biomedical Nanoengineering The recent success of large language models (LLMs) in performing natural language processing tasks has increased interest in applying generative artificial intelligence (AI) to scientific research. Ho...

Our latest publication led by Yifan Wang is now @acs.org on developing a generative #AI #LLM to help design #nanomedicine. @mdanderson.bsky.social @bettykimmdphd.bsky.social

BRAFV600E-Driven Lung Tumorigenesis Requires Ligand-Mediated Activation of ERBB Receptor Signaling Secretion of ligands of the human epidermal growth factor (EGFR) family of receptors or erythroblastic leukemia viral oncogene family (ERBB1-4) is a feature common to many cancer cells. However, our u...

I am thrilled to share that the first preprint from my lab is now available on bioRxiV! In this study, our team elucidates the role of autocrine ligands in the aberrant behavior of oncogene-driven lung cancer.

www.biorxiv.org/content/10.1...

NEW Preprint Watch from Annette Wu & @wenjiang-nano.bsky.social @preprintclub.bsky.social reporting on @biorxiv-immuno.bsky.social preprint by @colinraposo.bsky.social et al. showing that checkpoint blockade drives expansion of exhausted T cell clones that develop functional memory
rdcu.be/ek1kY

Sharing the latest commentary by our amazing PhD student Annette Wu @natrevimmunol.nature.com previewing exciting work from @stanfordmedicine.bsky.social on the formation of memory T cells in the setting of chronic stimulation. @mdanderson.bsky.social

Greatly enjoyed @twanlammers.bsky.social visiting Houston! Enjoying some classic Texan protein in preparation for his high caloric burning seminar.

Targeted STING Activation Using Modified Ultrasound‐Responsive Microbubbles Enhances Immune Checkpoint Blockade Against Melanoma This study explores the use of ultrasound contrast agents loaded with Stimulator of Interferon Genes (STING) agonists as an approach to activate the body's immune system against cancer. Termed Microb...

Our latest paper in collaboration with @jacques-lux.bsky.social describing using #US to activate #sting for #cancerimmunotherapy is now online in AdvScience. @mdanderson.bsky.social @utswtxid.bsky.social

An antibody–toxin conjugate enhances innate immune cell responses in tumors Nature Cancer - Traditional antibody–toxin conjugates (ATCs) are designed to target and destroy cancer cells. We present an ATC that acts on innate immune cells to promote tumor-cell...

Research briefing describing our latest paper is now online @naturecancer.bsky.social rdcu.be/ecf1I @mdanderson.bsky.social @ackoongmdphd.bsky.social @bettykimmdphd.bsky.social

MD Anderson researchers develop novel antibody-toxin conjugate Researchers at The University of Texas MD Anderson Cancer Center have developed a novel antibody-toxin conjugate (ATC) designed to stimulate immune-mediated eradication of tumors. According to preclin...

MD Anderson researchers have developed a novel antibody toxin-conjugate that’s not designed to kill the cancer cells directly.

Read how this new approach is designed to trigger the body's natural immune response instead: bit.ly/4bhtToM #EndCancer

An antibody–toxin conjugate targeting CD47 linked to the bacterial toxin listeriolysin O for cancer immunotherapy Nature Cancer - Schrank et al. report the design and characterization of an antibody–toxin conjugate targeting CD47, promoting anti-tumor immunity in preclinical cancer models.

Our newest article is online @naturecancer.bsky.social A new antibody drug conjugate that doesn’t kill tumor cells but rely on immune system to eradicate cancer. @bettykimmdphd.bsky.social @mdanderson.bsky.social

MD Anderson receives nearly $23 million in CPRIT funding for cancer research, faculty recruitment The University of Texas MD Anderson Cancer Center today was awarded nearly $23 million from the Cancer Prevention and Research Institute of Texas (CPRIT) in support of 20 cancer research projects to a...

MD Anderson is grateful to the Cancer Prevention and Research Institute of Texas for providing nearly $23 million to support our ongoing research and faculty recruitment.

Read about the research it will benefit: brnw.ch/21wQOF9 #EndCancer

Hanging out with old doctoral study advisor in Singapore. Talking about science over beautiful scenery and amazing food.

I wish I have a magic 8 ball that tells me before hand exactly which experiments that I should conduct that will yield positive results.

Multi-omics approaches to decipher the interactions of nanoparticles and biological systems - Nature Reviews Bioengineering The interactions of nanoparticles with the body are dynamic and complex. This Perspective examines the application of different multi-omics tools to investigate nano–bio interactions in vitro and in vivo.

Understanding how nanoparticles interact with biological systems is crucial for the development and implementation of nanoparticles in clinical settings. This article explores multi-omics approaches to decipher the interactions of nanoparticles and biological systems:
https://go.nature.co...

Congrats to @wenjiang-nano.bsky.social! Well deserved recognition. @MDAndersonNews #endcancer #radonc

Multi-omics approaches to decipher the interactions of nanoparticles and biological systems - Nature Reviews Bioengineering The interactions of nanoparticles with the body are dynamic and complex. This Perspective examines the application of different multi-omics tools to investigate nano–bio interactions in vitro and in v...

Finishing up 2024 with our latest paper in Nature Rev Bioengineering on using multiomic tools to study bio-nano interactions. @bettykimmdphd.bsky.social @mdanderson.bsky.social

Grateful for this holiday season. Especially for our family, friends, mentors and our trainees who fills us with joy, love, laughter and kindness. Our first attempt at roasting a turkey finally became reality at 9pm. #Thankful #SomeonesSmoked&RaginCajunTurkiesWereBetter
@wenjiang-nano.bsky.social

Great time tonight with guest Dolores Hambardzumyan and our colleagues Jason Schenkel, @wenjiang-nano.bsky.social
and #JPAI members @pamsharmamdphd.bsky.social @jimallisonphd.bsky.social
Xi Chen @mdanderson.bsky.social
#myeloid #GBM #endcancer

Nature biomedical engineering too!

Next-generation combination approaches for immune checkpoint therapy - Nature Immunology In this Review, Sharma and colleagues describe the current landscape of combination therapies and discuss requirements for the development of effective combination strategies.

www.nature.com/articles/s41...

Sharing our latest review article to highlight the importance of appropriately developing combination strategies for immune checkpoint therapy. Grateful for working with 3 brilliant scientists: Sangeeta Goswami, Kristen Pauken & Linghua Wang